JAK inhibitors plus standard of care vs placebo or usual care
Adverse events: all grades · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
- no estimate extracted3 studies · 1885 participantsModerate
Findings
What do systematic reviews say?
7 questions · 7 findings · 5 reviews · Haematology
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 28.6%Low 3 · 42.9%Moderate 2 · 28.6%High 0 · 0%
Vitamin D vs placebo or usual care
Adverse events: all grades · individuals with moderate to severe disease
It is very uncertain whether summary of Findings Table ‐ Vitamin D changes adverse events (any grade) compared with placebo or standard care alone (very low certainty).
1 finding from 1 review
- Vitamin D supplementation for the treatment of COVID‐19: a living systematic review 2021 · Cochrane Headline outcomes onlyRR 2.98 [0.12, 72.3]1 study · 237 participantsVery low
Summary of findings table ‐ Corticosteroids plus standard care vs placebo or usual care
Adverse events: all grades · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
- Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence 2022 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 447 participantsVery low
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo
Adverse events: all grades · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
- RR 0.99 [0.74, 1.31]1 study · 243 participantsLow
Remdesivir and standard care vs placebo or usual care
Adverse events: all grades · non‐hospitalised adults with mild COVID‐19
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
- RR 0.91 [0.76, 1.1]1 study · 562 participantsModerate
Remdesivir and standard care vs placebo or usual care
Adverse events: all grades · hospitalised individuals with COVID‐19 (moderate to severe disease)
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
- RR 1.04 [0.92, 1.18]4 studies · 2498 participantsLow
Hyperimmune immunoglobulin from human plasma vs saline placebo
Adverse events: all grades · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in adverse events of any grade up to 28 days (data only available for… compared with saline placebo (low certainty).
1 finding from 1 review
- RR 0.98 [0.81, 1.18]Studies not reportedLow